Ivosidenib in Treating Patients With Advanced Solid Tumors ...

Summary. This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the ...

Safety and activity of ivosidenib in patients with IDH1 ... - PubMed

Ivosidenib is an oral, targeted inhibitor of mutant IDH1 (mIDH1) approved in the USA for the treatment of mIDH1 acute myeloid leukaemia in newly diagnosed ...

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

The patient with a partial response had a nonenhancing tumor and received ivosidenib 500 mg once per day. The majority of patients had disease control, with a ...

Final Overall Survival Efficacy Results of Ivosidenib for Patients With ...

In a previous report, the IDH1-variant allele fraction from plasma circulating tumor DNA and the plasma D-2-hydroxyglutarate levels were ...

Clinical Trials Using Ivosidenib - NCI

This phase I trial tests the safety, side effects, and best dose of ivosidenib with modified FOLFIRINOX in treating patients with pancreatic cancer that can be ...

Ivosidenib in Treating Patients with Advanced Solid Tumors ...

OUTLINE: Patients receive ivosidenib orally (PO) once daily (QD). Cycles repeat every 28 days for up to 2 years in the absence of disease progression or ...

Full article: Ivosidenib, an IDH1 inhibitor, in a patient with recurrent ...

The use of ivosidenib in this study was associated with prolonged tumor control and tumor shrinkage in the patients with advanced glioma [Citation33].

Articles Safety and activity of ivosidenib in patients with IDH1-mutant ...

Ivosidenib is under clinical evaluation in a phase 1 study that aims to assess its safety and tolerability in patients with mIDH1 solid tumours.

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib

In patients with chondrosarcoma, ivosidenib showed minimal toxicity, substantial 2-HG reduction, and durable disease control.

Ivosidenib and Nivolumab for the Treatment of IDH1 Mutant Glioma ...

This phase II trial studies the effects of ivosidenib and nivolumab in treating patients with IDH1 mutant glioma and solid tumors that have spread to other ...

A phase 1, multicenter, randomized, open-label, perioperative study ...

• In an ongoing phase 1 study of ivosidenib in patients with advanced mIDH1 solid tumors (NCT02073994), including 66 patients with gliomas, ivosidenib.

Ivosidenib in IDH1-mutant, chemotherapy-refractory ... - The Lancet

... patients with advanced solid tumors. Invest New Drugs. 2020; 38:433 ... Combination versus mono-therapy as salvage treatment for advanced biliary ...

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an ...

... ivosidenib appears appropriate for the treatment of patients with advanced solid tumors with an IDH1 mutation. In patients with ...

UCSF IDH1 Gene Mutation Clinical Trials — San Francisco Bay Area

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in ...

Ivosidenib: A Review in Advanced Cholangiocarcinoma

The latest European Society for Medical Oncology Clinical Practice Guideline for the diagnosis, treatment and follow-up of biliary tract cancer ...

Ivosidenib in IDH1-mutant, chemotherapy-refractory ...

Ivosidenib (AG-120) is an oral, potent, targeted inhibitor of mutated IDH1 approved for patients with newly diagnosed acute myeloid leukaemia who are ineligible ...

Clinical Trial Details | Nebraska Medicine Omaha, NE

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial).

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

Methods. We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with mIDH1 solid tumors.

Press Release Details - Agios Pharmaceuticals, Inc.

TIBSOVO® is not approved in any country for the treatment of patients with advanced cholangiocarcinoma. About TIBSOVO® (ivosidenib). TIBSOVO® is indicated for ...

FDA Approves Ivosidenib for Advanced or Metastatic IDH1-Mutated ...

The trial demonstrated a statistically significant improvement in progression-free survival for patients randomly assigned to ivosidenib (hazard ...